Compare Lennar Corporation (LEN) vs Eli Lilly And Co (LLY) Price & Performance

Lennar (LEN) trades at $88.18, up 3.96% in the last session, with a bullish technical signal and support at $86. The stock shows mixed fundamentals: revenue declined to $34.19B in 2025, net income fell to $2.08B, and recent EPS misses occurred, but valuation ratios like P/E of 13.82 and P/B of 0.98 suggest potential undervaluation. A dividend of $0.50 is scheduled for July 2026, while cash flow turned negative in 2025 but is projected to recover in 2026.

Outlook is cautious; analyst consensus is a 'Buy' with a $84.30 price target, but risks include housing affordability pressures and earnings volatility. Upside hinges on execution amid high mortgage rates, with institutional interest noted from CalPERS' recent share acquisition.

Eli Lilly (LLY) trades at $1,185.71, down 0.59% on the day, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported Q2 2026 revenue growth of 48% to $23 billion, beating estimates, driven by demand for Mounjaro and Zepbound. Valuation ratios like P/E of 39.8 and P/S of 13.34 reflect high growth expectations, while profitability remains robust with a net income margin of 33.53%.

Outlook is positive due to pipeline advancements like retatrutide and raised 2026 guidance, but risks include competitive pressures and regulatory scrutiny. Analysts are bullish with a consensus price target of $1,380, citing sustained double-digit growth and market leadership in weight-loss drugs as key drivers for upside.